DRI nears $850m for Fund III

The pharmaceutical royalties-focused firm aims to hold a final close on $1bn by the end of the first quarter.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this